Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5086
Preliminary research indicates that stem cells may be removed from patients undergoing radiation or chemotherapy, and then transplanted back into the patient using the Licensed CD77 Technology. Shiga-like toxin 1, a bacterial toxin, is used as an agent to selectively kill cancer cells in the patientâ€™s bone marrow without harming the essential marrow cells which allow regeneration of marrowâ€™s capacity for forming blood cells.
IPSCIO Record ID: 3624
IPSCIO Record ID: 3285
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who responded to initial treatment with CVP chemotherapy
IPSCIO Record ID: 27461
The treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.
IPSCIO Record ID: 28789
IPSCIO Record ID: 26630
Also included in the License are the rights to use the PLX I technology in Stem Cell's in-vitro screening applications, if any, worldwide.